Abcuro
Lusi graduated Suffolk University with a degree in Accounting and Finance. After graduating, she worked at Harvard University Press as a Cost Accountant for 3 years. While working at Harvard, Lusi was able to study and fulfill the requirements for her CPA license. She then transitioned to the Cannabis industry as a Staff Accountant at Sira Naturals. Sira Naturals was a start-up at the time she joined, and she was able to help in developing processes and procedures regarding AP, AR, Leases, Fixed Assets, and budgeting.
This person is not in any offices
Abcuro
2 followers
Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ABC008, a first-in-class anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy muscle tissue in patients with inclusion body myositis (IBM), into clinical studies.